Statement: Reaction to Public Hearing on Pennsylvania Senate Bill 675

Last Updated: Nov 19, 2019

The following is a statement from Lawrence John, MD, president of the Pennsylvania Medical Society. He reacts to Tuesday’s public hearing on legislation (Senate Bill 675) that seeks to impose additional barriers to physicians who prescribe buprenorphine for medication assisted treatment:
John“Pennsylvanians suffering from opioid use disorder deserve access to the most proven treatment, and medication assisted treatment (MAT) has become the gold standard. However, Senate Bill 675 threatens access to MAT by creating additional hurdles for physicians who prescribe and dispense buprenorphine. 
Physicians and other medical professionals must already obtain a DEA-approved buprenorphine waiver training certification in order to provide office-based medication assisted treatment to patients who suffer from opioid use disorder. 
Senate Bill 675 would impose duplicative state requirements and additional costs that may discourage physicians and medical professionals from continuing in this program. No other medication or condition requires a physician to obtain an additional state license.
While the Pennsylvania Medical Society opposes Senate Bill 675, we are committed to working with the state legislature to ensure Pennsylvania’s addiction treatment system is aligned with the standards and best practices utilized within the addiction medicine field.
We are making progress in this epidemic. Senate Bill 675 would be a step backward in this effort.”
#     #     #
Media Contact
Jeff Wirick
Pennsylvania Medical Society
The Pennsylvania Medical Society helps its 22,000 physician and medical student members return to the art of medicine through advocacy and education. Learn more by visiting or by following us on Twitter at @PAMEDSociety. 

Login to be able to comment

Leave a comment

Norcal Mutual

Learn More